Intellia Therapeutics Faces Safety and Efficacy Challenges with Nex-Z: Analyst Issues Sell Rating

Goldman Sachs analyst Salveen Richter maintained a Sell rating on Intellia Therapeutics (NTLA – Research Report) today and set a price target of $8.00.

Salveen Richter has given his Sell rating due to a combination of factors surrounding Intellia Therapeutics’ recent developments. The primary concern stems from a safety incident in the Phase 3 MAGNITUDE study, where a patient experienced significant liver enzyme elevations after receiving the CRISPR gene editing therapy, nexiguran ziclumeran (nex-z). Although the condition appears to be resolving without severe consequences, the recurrence of such events raises questions about the therapy’s long-term safety profile.
Furthermore, the competitive landscape poses challenges for Intellia. The efficacy of nex-z does not significantly differentiate it from existing siRNA therapies, such as ALNY’s Amvuttra. This lack of clear superiority, combined with safety concerns, casts doubt on the commercial viability of nex-z. The market will be closely watching upcoming data from ongoing studies to assess the therapy’s durability and potential to offer a functionally curative solution.

According to TipRanks, Richter is a 4-star analyst with an average return of 8.6% and a 41.69% success rate. Richter covers the Healthcare sector, focusing on stocks such as Biogen, Regeneron, and Crispr Therapeutics AG.